Do patients Rezum medications?-a real-world analysis of medical retreatment after water vapor thermal therapy
Abstract
Background: Little is known regarding medical retreatment rates after water vapor thermal therapy (WVTT; Rezum, Boston Scientific, Marlborough, MA, USA) for benign prostatic hyperplasia (BPH). We sought to identify incidence and predictors of medical retreatment for symptomatic recurrence among this population.
Methods: We performed a single institution retrospective review of patients who underwent WVTT by a single surgeon from July 2018 to January 2024. We excluded patients with prostate volume >80 cc. Primary outcome was medical retreatment, defined as initiation or resumption of any BPH medication following WVTT.
Results: We identified 155 patients with mean age 67.4±10.3 years and prostate volume 46.4±13.6 cc. Forty-eight (31%) patients underwent medical retreatment within mean follow up of 19.5 months. Mean time to retreatment was 9.8 months. Alpha blockers were the most commonly restarted medication (40.5%), followed by daily tadalafil (25.5%) and 5-alpha reductase inhibitors (10.6%); 23.4% of patients restarted multiple medications. Preoperative use of alpha blockers (95.8% vs. 84.1%; P=0.04), 5-alpha reductase inhibitors (39.6% vs. 23.4%; P=0.04) and daily tadalafil (35.4% vs. 15.0%; P=0.004) significantly predicted medical retreatment. At 3 months, International Prostate Symptom Scores (IPSS) total (15.5±7.9 vs. 9.8±6.1, P=0.002) and quality of life (QoL) (3.2±1.6 vs. 2.4±1.5, P=0.05) were significantly higher in the medical retreatment group. Surgical retreatment…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 155 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.